» Articles » PMID: 11169454

Cervical Cancer Vaccines: Emerging Concepts and Developments

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2001 Feb 13
PMID 11169454
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Certain human cancers are linked to infection by oncogenic viruses that are able to cause transformation of the normal host cell into a cancerous cell. Human papillomavirus (HPV) DNA and expression of viral transforming proteins are found in virtually all cervical cancer cells, indicating an important role of this virus in the pathogenesis of the disease. Evidence exists that the immune response to cancer cells can play a major role in determining the outcome of disease. The fact that HPV is a necessary cause for cervical cancer provides a clear opportunity to develop a therapeutic vaccine against the virus to treat patients with cervical cancer at its early and late stages. Development of a prophylactic vaccine for HPV would also reduce the incidence of cervical neoplasias by preventing virus infection. Various candidate HPV vaccines are being developed and tested in animal models and/or in human clinical trials. These HPV vaccines, both preventive and therapeutic, are the subjects of this review.

Citing Articles

Mathematical Modeling and Computational Prediction of High-Risk Types of Human Papillomaviruses.

Zhang J, Wang K Comput Math Methods Med. 2022; 2022:1515810.

PMID: 35912141 PMC: 9334084. DOI: 10.1155/2022/1515810.


HPVMD-C: a disease-based mutation database of human papillomavirus in China.

Yang Z, Yi W, Tao J, Liu X, Zhang M, Chen G Database (Oxford). 2022; 2022.

PMID: 35348640 PMC: 9216535. DOI: 10.1093/database/baac018.


Vaccination Against Cervical Cancer: Hopes and Realities.

Da Silva D, Kast W Am J Cancer (Auckl). 2021; 4(4):207-219.

PMID: 34566405 PMC: 8462130. DOI: 10.2165/00024669-200504040-00001.


CRISPR/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6.

Yoshiba T, Saga Y, Urabe M, Uchibori R, Matsubara S, Fujiwara H Oncol Lett. 2019; 17(2):2197-2206.

PMID: 30675284 PMC: 6341785. DOI: 10.3892/ol.2018.9815.


Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.

Sato N, Saga Y, Uchibori R, Tsukahara T, Urabe M, Kume A Int J Oncol. 2018; 52(3):687-696.

PMID: 29344635 PMC: 5807046. DOI: 10.3892/ijo.2018.4245.